OPRXOptimizeRx Corp.
The Read
9% post-Q1 2026 as EPS met estimates without a clear beat or guidance update.
The schedule
- Thu15Oct
Assessment of Q4 and FY27 pharma marketing budget commitments ahead of the year-end spend cycle.
- Thu14Jan
Annual JPM presentation, highly scrutinized for forward guidance hints, new network partnerships, or M&A signaling.
- Sat13Feb
Q3 results release, providing critical visibility into late-year pipeline conversions and profitability metrics.
- Sun14Feb
Full-year 2026 wrap-up and the formal issuance of FY27 revenue and earnings guidance.
- Wed12May
Initial fundamental check for FY27 execution, assessing whether the company has reversed its prior-year revenue contractions.
Past
- Fri14Aug
Market evaluation of Q2 fundamentals, focusing on EHR network programmatic adoption amid trailing negative revenue growth.
- Wed13May
Actual outcome: Bear · $5.21 at outcome
OptimizeRx reported Q1 2026 EPS of $0.27, exactly meeting consensus estimates amid pre-earnings concerns of softer trends and declining revenue forecasts. While the company subsequently announced the launch of programmatic access to its EHR advertising network, the lack of a clear earnings beat or significant guidance update resulted in a muted price reaction, with shares hovering around $6.21 and failing to reach the $7.00 bull target.
- Thu12Mar
Actual outcome: Bull · $6.31 at outcome
OptimizeRx reported strong Q4 2025 financial results, delivering an earnings and revenue beat that highlighted solid fundamental performance. Although shares initially faced pressure from warnings regarding Most Favored Nation pricing uncertainty, the stock rebounded and rose 6.4% during the target window, further bolstered by its addition to the Zacks Strong Buy value stocks list.